Alopecia Areata Incognita: Current Evidence
Abstract
INTRODUCTION: Alopecia areata incognita (AAI) represents a distinct subtype of alopecia areata (AA), characterized by profound hair shedding and diffuse thinning. Despite being initially described in 1987, AAI remains underdiagnosed, with limited published reports. This comprehensive review aims to consolidate the current evidence concerning AAI pathogenesis, clinical presentation, trichoscopic and histopathologic attributes, differential diagnoses, and available treatment modalities.
METHODS: PubMed searches were performed to identify all articles discussing AAI published up to September 2024.
RESULTS: We identified 28 articles encompassing AAI epidemiology, pathogenesis, clinical presentation, trichoscopic findings, histopathologic characteristics, diagnosis, and treatment options.
LIMITATIONS: The data primarily stem from observational studies, case reports, case series, and a pilot study. The establishment of diagnostic criteria and treatment protocols necessitates more extensive and well-controlled studies.
CONCLUSION: Alopecia areata incognita is a distinctive form of AA, sharing similarities with telogen effluvium (TE) and showing potential associations with androgenetic alopecia (AGA). It has an acute onset and results in sudden diffuse hair loss. While diagnostic challenges persist, combining clinical, trichoscopic, and histopathologic evaluations aids in accurate identification. AAI typically responds favorably to topical steroids and has a better prognosis than…
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.